AMA.A.K.A.N.S.H.R.A.H.U.L. Maheshwari

A.A.K.A.N.S.H.R.A.H.U.L. Maheshwari

*This is an algorithmically generated author record based on publicly available information.

A.A.K.A.N.S.H.R.A.H.U.L. Maheshwari has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Emerging artificial intelligence-aided diagnosis and management methods for ischemic strokes and vascular occlusions: A comprehensive review

    by G.A.U.R.I. Parvathy, B.A.L.A.K.R.I.S.H.N.A.N. Kamaraj, B.I.K.I.K.U.M.A.R. Sah, A.A.K.A.N.S.H.R.A.H.U.L. Maheshwari, A.I.S.W.A.R.I.Y.A.A.N.N.A. Alexander, V.I.N.D.H.E.S.H. Dixit, H.A.S.S.A.N. Mumtaz, M.U.H.A.M.M.A.D. Saqib


  • Open Access

    Mechanical thrombectomy for AIS from large vessel occlusion – current trends and future perspectives

    by Gauri Parvathy, Rohit Chandra Dey, Lakshmi Venkata Simhachalam Kutikuppala, Aakansh Rahul Maheshwari, Elwy Josey, Jyothi Swaroop Chintala, Mohammed Abdullah, Swathi Godugu

    Stroke is found to be one of the global top causes of mortality and the major factor in years of life with a handicap (DALYs). Ischemic strokes contributed to nearly 70% of all strokes worldwide. For endovascular thrombectomy in acute ischemic stroke with large vessel obstruction (AIS-LVO), using stent retrievers and/or reperfusion catheters has become the gold standard of therapy. The methodology involved keyword-based search in databases like PubMed, Embase, and Google Scholar for recent publications on mechanical thrombectomy (MT), AIS, large vessel occlusion (Large Vessel Occlusion (LVO)), screening relevant articles, retrieving full texts, and synthesizing key findings on procedural advancements, patient selection, COVID-19 (coronavirus disease 2019) impact, delay effects, effectiveness, clinical outcomes, and future perspectives. Only people with substantial cerebral artery obstruction may do well from MT. This includes the distal carotid artery and the proximal middle cerebral artery (segment M1). The size of a blocked vessel and NIHSS (National Institute of Health Stroke Scale) score are directly connected. Both the 2018 and 2019 versions of the AHA/ASA (American Heart Association/American Stroke Association) Guidelines for the Early Management of Patients with Acute Ischemic Stroke contained the recommendations that cases with AIS-LVO get endovascular therapy when administered during the time frame of 0–6 h after onset (Grade IA evidence). It is questionable whether this group of patients can be managed without the need for intravenous tissue plasminogen activator at the onset. When functional independence [modified Rankin Scale (mRS) score 2] was present at long-term follow-up, the endovascular intervention was favored. Tenecteplase, which differs from alteplase in terms of genetic variation, has a greater half-life and a higher level of fibrin selectivity, enabling bolus infusion. Studies have also demonstrated its efficacy and safety, as well as its long-term cost-effectiveness.


  • Open Access

    Raynaud’s Phenomenon as the Initial and Only Manifestation of Non-Hodgkin Lymphoma: A Case Report

    by Gauri Parvathy, D.H.J.P.Uresha Lakshani, Asadullah Khan, Aakansh Maheshwari, Kaivan Patel

    Raynaud’s phenomenon is one of the commonest manifestations of rheumatic diseases. However, it can be caused by non-Rheumatic conditions as well. Among non-rheumatic causes, cancers are widely reported as the culprit”. Raynaud’s phenomenon caused by non-rheumatic diseases are commonly resistant to standard treatment options They are associated with more severe infections. Among non-rheumatic causes, cancers are widely reported as the culprit. We present a case of non-Hodgkin lymphoma presenting solely with Raynaud’s phenomenon.